Furthermore, treatment with ATH-1105 increased the expression of the glutamate transporter EAAT2, which is a key player in the maintenance of physiological glutamate levels and is reduced in people with ALS (Rothstein et al., 1995; Rosenblum and Trotti, 2017). Here, SLC1A2 is linked to amyotrophic lateral sclerosis.